Free Trial

AbCellera Biologics (ABCL) Competitors

AbCellera Biologics logo
$2.00 +0.01 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+1.00%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABCL vs. HCM, AMRX, OGN, MIRM, APLS, DNLI, VCEL, AAPG, NAMS, and KYMR

Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

AbCellera Biologics vs.

HUTCHMED (NASDAQ:HCM) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.

HUTCHMED has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. HUTCHMED's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMEDN/A N/A N/A
AbCellera Biologics -533.32%-15.73%-12.22%

In the previous week, AbCellera Biologics had 7 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for AbCellera Biologics and 1 mentions for HUTCHMED. AbCellera Biologics' average media sentiment score of 0.56 beat HUTCHMED's score of 0.28 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AbCellera Biologics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

HUTCHMED received 260 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.00% of users gave AbCellera Biologics an outperform vote while only 66.18% of users gave HUTCHMED an outperform vote.

CompanyUnderperformOutperform
HUTCHMEDOutperform Votes
317
66.18%
Underperform Votes
162
33.82%
AbCellera BiologicsOutperform Votes
57
76.00%
Underperform Votes
18
24.00%

HUTCHMED has higher revenue and earnings than AbCellera Biologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED$630.20M3.67$100.78MN/AN/A
AbCellera Biologics$23.11M25.82-$146.40M-$0.56-3.57

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

HUTCHMED presently has a consensus target price of $19.00, indicating a potential upside of 43.18%. AbCellera Biologics has a consensus target price of $8.33, indicating a potential upside of 316.67%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
AbCellera Biologics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

HUTCHMED has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Summary

AbCellera Biologics beats HUTCHMED on 9 of the 16 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABCL vs. The Competition

MetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$596.85M$6.49B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-3.289.1826.8919.71
Price / Sales25.82252.26386.75120.59
Price / CashN/A65.8538.2534.62
Price / Book0.506.456.774.50
Net Income-$146.40M$144.21M$3.23B$248.22M
7 Day Performance-0.99%2.46%1.82%0.56%
1 Month Performance-20.63%4.59%11.12%13.17%
1 Year Performance-48.19%-2.68%17.09%7.30%

AbCellera Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABCL
AbCellera Biologics
2.7477 of 5 stars
$2.00
+0.5%
$8.33
+316.7%
-48.3%$596.85M$23.11M-3.28500Gap Up
HCM
HUTCHMED
2.237 of 5 stars
$13.92
-2.0%
$19.00
+36.5%
-33.6%$2.43B$630.20M0.001,760News Coverage
Positive News
Analyst Downgrade
Gap Down
AMRX
Amneal Pharmaceuticals
3.27 of 5 stars
$7.60
+2.6%
$11.50
+51.3%
+8.7%$2.36B$2.83B-11.187,600Positive News
OGN
Organon & Co.
4.7484 of 5 stars
$8.69
+0.0%
$18.00
+107.1%
-61.3%$2.26B$6.29B2.6110,000High Trading Volume
MIRM
Mirum Pharmaceuticals
4.0842 of 5 stars
$45.57
+2.9%
$59.00
+29.5%
+71.8%$2.25B$379.25M-22.56140News Coverage
Positive News
Analyst Forecast
Analyst Revision
APLS
Apellis Pharmaceuticals
4.2031 of 5 stars
$17.52
+1.2%
$41.37
+136.2%
-59.1%$2.20B$781.37M-8.63770Positive News
Analyst Forecast
DNLI
Denali Therapeutics
4.4978 of 5 stars
$14.80
+3.0%
$33.79
+128.3%
-31.5%$2.15B$330.53M-5.36430Analyst Forecast
Gap Up
VCEL
Vericel
2.6898 of 5 stars
$42.67
+2.3%
$60.86
+42.6%
-20.3%$2.14B$238.54M711.29300News Coverage
Positive News
Analyst Forecast
AAPG
Ascentage Pharma Group International
N/A$24.29
-0.1%
N/AN/A$2.11B$980.65M0.00600Positive News
Gap Down
NAMS
NewAmsterdam Pharma
2.6839 of 5 stars
$19.16
+4.3%
$43.00
+124.4%
-5.0%$2.10B$45.56M-10.194Analyst Downgrade
Gap Up
KYMR
Kymera Therapeutics
2.7503 of 5 stars
$32.17
+7.0%
$55.53
+72.6%
-14.7%$2.09B$47.07M-13.75170Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ABCL) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners